HF
MLTX icon

HRT Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

HRT Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$415K Buy
+22,300
New +$369K ﹤0.01% 2661

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial's MLTX Position: Q1 2026 in Review

HRT Financial reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q1 2026, selling an estimated $2.46M and leaving 487,583 shares worth $9.09M. The position accounts for 0.02% of the portfolio, ranked #663.

HRT Financial first reported a position in MLTX in Q4 2020 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • HRT Financial held 487,583 shares of MoonLake Immunotherapeutics worth $9.09M as of Q1 2026.
  • HRT Financial sold 148,318 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.46M.
  • MoonLake Immunotherapeutics made up 0.02% of HRT Financial's portfolio in Q1 2026, its #663 holding.
  • HRT Financial first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 11 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.